{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-213225","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2024-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.918835+00:00","generated_at":"2026-05-31T06:26:58.817553+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Bolt Biotherapeutics appoints Dr. Jakob Dupont to Board; two directors resign","bullets":["James Healy, M.D., Ph.D., resigned from Board effective Sept 3, 2024; no disagreement with company.","Frank D. Lee also resigned from Board effective Sept 3, 2024; no disagreement with company.","Board appointed Jakob Dupont, M.D., Ph.D., as Class II director effective Sept 3, 2024.","Dr. Dupont is Executive Venture Partner at Sofinnova Investments; former Global Head of R&D at Atara Bio."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-213225","json":"https://secwatch.observer/filing/0001193125-24-213225.json","markdown":"https://secwatch.observer/filing/0001193125-24-213225.md","text":"https://secwatch.observer/filing/0001193125-24-213225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000119312524213225/0001193125-24-213225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000119312524213225/d886159d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:26:58.817553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33cfe7ba45","claim":"Jakob Dupont was appointed as Class II member of the Board at Bolt Biotherapeutics, Inc..","evidence_excerpt":"Effective September 3, 2024, the Board appointed Jakob Dupont, M.D., Ph.D., to serve as a Class II member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312524213225/0001193125-24-213225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II member of the Board"}],"fact_type":"executive_change"},{"claim_id":"59db0c287b","claim":"Frank D. Lee resigned as member of the Board at Bolt Biotherapeutics, Inc..","evidence_excerpt":"On September 1, 2024, Frank D. Lee notified the Company of his resignation as a member of the Board and the committees thereof, effective as of September 3, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312524213225/0001193125-24-213225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the Board"}],"fact_type":"executive_change"},{"claim_id":"b1cea687cb","claim":"James Healy resigned as member of the Board at Bolt Biotherapeutics, Inc..","evidence_excerpt":"On August 28, 2024, James Healy, M.D., Ph.D., notified Bolt Biotherapeutics, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and the committees thereof, effective as of September 3, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312524213225/0001193125-24-213225-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}